‘‘
Dymistaaah
‘‘
Twice the relief of allergic rhinitis symptoms compared with an intranasal corticosteroid * 1, 2
* Compared to fluticasone propionate( FP). Reflective total 7 symptoms score( rT7SS) compared to FP( p = 0.0013) at day 14, post-hoc analysis, placebo subtracted results( n = 610).
PBS Information: This product is not listed on the PBS.
Please review Product Information( PI) before prescribing. Full PI is available on request by calling 1800 314 527 or at: www. ebs. tga. gov. au
Dymista ® 125 / 50( azelastine hydrochloride 125 µ g / fluticasone proprionate 50 µ g) nasal spray 17mL, 120 sprays). Indications: Symptomatic treatment of moderate to severe allergic rhinitis and rhino-conjunctivitis in adults and children 12 years and older where use of a combination( intranasal antihistamine and glucocorticoid) is appropriate. Dosage: Adults and adolescents( ≥ 12yrs): One spray in each nostril twice daily. Contraindications: Hypersensitivity to the active substance( s) or excipients. Precautions: Pregnancy( Cat B3) and lactation; operating machinery or driving motor vehicle; use with alcohol or other CNS depressants, somnolence; patients with recent nasal ulcers, surgery or injury to nose or mouth; patients susceptible to candida infections( e. g. diabetics); glaucoma and / or cataracts; HPA axis effect / suppression, adrenal function impairment; tuberculosis or untreated respiratory infection; children and adolescents(< 12yrs); severe hepatic and renal impairment. Interactions: Cytochrome P450 CYP3A4 inhibitors( potential increase fluticasone proprionate exposure) eg: ritonavir, ketoconazole, cimetidine; CNS depressants. Adverse Effects: Common: headache, dysgeusia, unpleasant smell; Uncommon: epistaxis, nasal discomfort, sneezing, nasal dryness, cough, dry throat and irritation; Very rare: somnolence; nasal septal perforation; hypersensitivity including anaphylactic reactions, angioedema and bronchospasm. Min PI Updated: 05 Jun 2017.
References: 1. Hampel FC et al. Ann Allergy Asthma Immunol 2010; 105:168 – 173. 2. Meltzer E et al. Int Arch Allergy Immunol 2013; 16:369 – 377.
Dymista ® is a registered trademark. MEDA Pharmaceuticals( Aust) Pty Ltd.( A Mylan Company). Level 1, 30 – 34 Hickson Rd, Millers Point, NSW, 2000, Australia. ABN: 29 601 608 771. Call: 1800 314 527. BB MYL2110A. DYM-2017-0234. Date of preparation: August 2017.